- Intestinal and Hepatic Niemann-Pick C1-Like 1
-
Park SW
- KMID: 2174264
- Diabetes Metab J.
- 2013 Aug;37(4):240-248.
- doi: 10.4093/dmj.2013.37.4.240
Polytopic transmembrane protein, Niemann-Pick C1-Like 1 (NPC1L1) is localized at the apical membrane of enterocytes and the canalicular membrane of hepatocytes. It mediates intestinal cholesterol absorption and prevents extensive loss... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients
-
Oh MS, Min YJ, Kwon JE, Cho EJ, Kim JE, Lee WS, Lee KJ, Kim SW, Kim TH, Kim CJ, Ryu WS
- KMID: 2297932
- Korean Circ J.
- 2011 May;41(5):253-258.
- doi: 10.4070/kcj.2011.41.5.253
BACKGROUND AND OBJECTIVES: Ezetimibe alone does not decrease C-reactive protein (CRP) levels in hypercholesterolemic patients. However, several reports have suggested that ezetimibe might potentiate the effect of statin not only... -
- CITED
-
- Close
- SHARE
-
- Close
- Familial Hypercholesterolemia and the Atherosclerotic Disease
-
Kim YR, Han KH
- KMID: 2224895
- Korean Circ J.
- 2013 Jun;43(6):363-367.
- doi: 10.4070/kcj.2013.43.6.363
Familial hypercholesterolemia (FH) is associated with premature atherosclerotic cardiovascular diseases, and is inherited as an autosomal dominant trait. The prevalence of heterozygous FH is one in five hundred people. Owing... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of ezetimibe on lipid profiles and hemostatic markers in end-stage renal disease
-
Park KS, Yeo YS, Yoo MH, Choi JS, Jang JW, Boo SJ, Yoo DJ, Kim SB
- KMID: 2258370
- Korean J Med.
- 2009 Oct;77(4):461-471.
BACKGROUND/AIMS: Dyslipidemia is one of the major causes of cardiovascular disease in end-stage renal disease (ESRD) patients. Most of them are dyslipidemic despite the use of lipid-lowering agents. Ezetimibe is... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk
-
Cho YK, Hur SH, Han CD, Park HS, Yoon HJ, Kim H, Nam CW, Kim YN, Kim KB, Park NH, Park HJ
- KMID: 2225129
- Korean Circ J.
- 2011 Mar;41(3):149-153.
- doi: 10.4070/kcj.2011.41.3.149
BACKGROUND AND OBJECTIVES: Although recent lipid-lowering therapies are effective in reducing low density lipoprotein-cholesterol (LDL-C) levels, many patients treated with lipid-lowering agents do not achieve target LDL-C levels, especially in... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Statins on the Epicardial Fat Thickness in Patients with Coronary Artery Stenosis Underwent Percutaneous Coronary Intervention: Comparison of Atorvastatin with Simvastatin/Ezetimibe
-
Park JH, Park YS, Kim YJ, Lee IS, Kim JH, Lee JH, Choi SW, Jeong JO, Seong IW
- KMID: 2177312
- J Cardiovasc Ultrasound.
- 2010 Dec;18(4):121-126.
- doi: 10.4250/jcu.2010.18.4.121
BACKGROUND: Epicardial fat is a visceral thoracic fat and known to be related with presence of dyslipidemia and coronary arterial stenosis. We evaluated the effects and differences of statins on... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model
-
Cho JS, Jeong MH, Sim DS, Hong YJ, Lim KS, Kim JH, Kim HD, Baek JY, Yoon HJ, Her SH, Jin SW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC
- KMID: 1713955
- J Korean Med Sci.
- 2010 May;25(5):716-722.
- doi: 10.3346/jkms.2010.25.5.716
The aim of this study was to examine the anti-proliferative and anti-inflammatory effects of ezetimibe/simvastatin (E/S) after drug-eluting stent (DES) implantation in a porcine coronary restenosis model. Pigs were randomized... -
- CITED
-
- Close
- SHARE
-
- Close
- The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
-
Yoon HE, Song JC, Hyoung BJ, Hwang HS, Lee SY, Jeon YJ, Choi BS, Kim YS, Yang CW
- KMID: 1717947
- Korean J Intern Med.
- 2009 Sep;24(3):233-237.
- doi: 10.3904/kjim.2009.24.3.233
BACKGROUND/AIMS: The efficacy and safety of a combination of ezetimibe and low-dose statin as primary treatment for dyslipidemia in renal transplant patients were evaluated prospectively. METHODS: The study enrolled 77... -
- CITED
-
- Close
- SHARE
-
- Close
